Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
2.280
-0.060 (-2.56%)
Nov 28, 2025, 4:00 PM EST - Market closed
Cardiff Oncology Revenue
Cardiff Oncology had revenue of $120.00K in the quarter ending September 30, 2025, a decrease of -27.27%. This brings the company's revenue in the last twelve months to $501.00K, down -27.18% year-over-year. In the year 2024, Cardiff Oncology had annual revenue of $683.00K with 39.96% growth.
Revenue (ttm)
$501.00K
Revenue Growth
-27.18%
P/S Ratio
289.16
Revenue / Employee
$15,182
Employees
33
Market Cap
153.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 683.00K | 195.00K | 39.96% |
| Dec 31, 2023 | 488.00K | 102.00K | 26.42% |
| Dec 31, 2022 | 386.00K | 27.00K | 7.52% |
| Dec 31, 2021 | 359.00K | -7.00K | -1.91% |
| Dec 31, 2020 | 366.00K | 121.37K | 49.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CRDF News
- 4 days ago - Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 22 days ago - Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update - GlobeNewsWire
- 24 days ago - Cardiff Oncology to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Cardiff Oncology: Preparing For A Defining 2026 - Seeking Alpha
- 5 weeks ago - Cardiff Oncology's Promising Cancer Breakthrough Ahead - Why I Choose To Buy - Seeking Alpha
- 3 months ago - Cardiff Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Cardiff Oncology (CRDF) Q2 Loss Down 19% - The Motley Fool
- 4 months ago - Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data? - Benzinga